Aligos Therapeutics Stock
Aligos Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Lawrence Blatt
- Employees
- 82
- Market cap
- $30 M
- IPO
- 16/10/2020
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently…
Aligos Therapeutics stock: price history
1D
-9.8%
1W
-9.0%
1M
-3.8%
6M
-27.2%
YTD
-47.9%
1Y
-53.8%
2Y
-34.1%
5Y
-98.8%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~5% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 16/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BearishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Aligos Therapeutics
Analyst assessment of Aligos Therapeutics
PRICE TARGET LOW
US$20.00
CONSENSUS
US$20.00
MEDIAN
US$20.00
PRICE TARGET HIGH
US$20.00
0
STRONG BUY
3
BUY
2
HOLD
0
SELL
0
STRONG SELL
5
TOTAL · Buy
As of: 11/03/2026
Aligos Therapeutics stock metrics
P/E
-0.67
P/B
1.59
EV/EBITDA
-0.05
RETURN ON EQUITY
-4.7%
NET MARGIN
-5.4%
DEBT/EQUITY
0.11
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
77.7%
FLOAT SHARES
4,852,872
AVG. DAILY VOLUME (30D)
41,486
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Aligos Therapeutics stock
What does Aligos Therapeutics do?
Aligos Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Lawrence Blatt, the company employs around 82 people.
The IPO was on 16/10/2020; the stock trades on NASDAQ under the ticker ALGS.
What do analysts say about Aligos Therapeutics stock?
5 analysts rate the stock, the consensus is Buy (as of 11/03/2026).
The average price target is US$20.00, ranging from US$20.00 to US$20.00, with a median of US$20.00.
This is an external assessment, not a statement by Market Jury.
When does Aligos Therapeutics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 5% stronger than usual.
Does Aligos Therapeutics pay a dividend?
No, Aligos Therapeutics currently does not pay a dividend.
Which stocks are comparable to Aligos Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Aligos Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Aligos Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.